Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 8 of 8 for “"EGFR TKI"”.

  1. A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer

    … in 60% of these cases. Also, over-expression of EGFR correlates with poor patient prognosis. Unfortunately, inhibitors of EGFR have shown little clinical efficacy in basal-type breast cancers. We have utilized basal-type breast cancer cell lines to determine a potential mechanism of resistance to …

    wayne-thes Repository record for A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer (opens in a new tab)

  2. Novel Mechanisms of Kinase Independent Pro-Survival Functions of EGFR in Cancer

    … activity of epithelial growth factor receptor (EGFR) plays an important role in regulating numerous signaling pathways in cancer. It is commonly overexpressed in various cancers. Several strategies for cancer therapy were developed to target the kinase function of EGFR. However, the …

    houston Repository record for Novel Mechanisms of Kinase Independent Pro-Survival Functions of EGFR in Cancer (opens in a new tab)

  3. Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance

    … such as epidermal-like growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) or monoclonal antibodies targeting vascular endothelial growth factor (VEGF/R), can effectively inhibit upregulated signaling pathways driving tumorigenesis in NSCLC and many other cancers. Unfortunately, …

    uthsc Repository record for Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance (opens in a new tab)

  4. EGFR in Early Non-small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial

    EGFR TKIs are standard therapy for advanced NSCLC. In order to define their role in early disease, we implemented a phase II trial of neoadjuvant gefitinib in clinical stage I NSCLC. Tumour shrinkage was seen in 43% of patients, with 11% achieving RECIST partial response (PR). Analysis of molecular …

    toronto-retro Repository record for EGFR in Early Non-small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial (opens in a new tab)

  5. Flourescent Biosensor-Based, Cdc42 Activity Imaging For Understanding the Regulation of Epidermal Growth Receptor (EGFR) Signalling in Head and Neck Cancer

    The Epidermal Growth Factor Receptor (EGFR) is overexpressed in several solid tumours including squamous cell carcinoma of the head & neck (SCCHN). Drugs that directly block the action of EGFR are currently available. However, a major unanswered question is; how best to select patients most likely …

    kings Repository record for Flourescent Biosensor-Based, Cdc42 Activity Imaging For Understanding the Regulation of Epidermal Growth Receptor (EGFR) Signalling in Head and Neck Cancer (opens in a new tab)

  6. The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistance in breast cancer

    … no correlation was found between HER-2, IGF-IR, EGFR expression or phosphorylation and response to Tmab. However, both HER-2 and phospho-HER-2 levels were found to correlate positively with phospho-IGF-IR levels (HER-2, p = 0.16; p-HER-2, p = 0.002). Tmab (T)-resistant cells showed reduced …

    dcu Repository record for The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistance in breast cancer (opens in a new tab)

  7. Epidemiology of non-squamous non-small cell lung cancer in New Zealand: A focus on EGFR gene mutation

    … Treatment with Tyrosine Kinase Inhibitors (TKIs) that target Epidermal Growth Factor Receptor (EGFR) significantly improves disease outcomes for non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with EGFR mutation. A better understanding is needed of the epidemiology of lung cancer in …

    auckland-ms Repository record for Epidemiology of non-squamous non-small cell lung cancer in New Zealand: A focus on EGFR gene mutation (opens in a new tab)

  8. Part I: Steroid Receptor CO-Activator 3 (SRC-3) Expression in Lung Cancer and its Role in Regulating Cancer Cell Survival and Proliferation; Part II: Development of Phosphospecific Peptoid Ligand

    … SRC-3 knockdown is "synthetically lethal" to EGFR-TKI-resistant cells. Together these data indicate that SRC-3 is an important new oncogene and therapeutic target for lung cancer. PART II: DEVELOPMENT OF PHOSPHOSPECIFIC PEPTOID LIGAND Most proteins can exist in a variety of …

    utswmed Repository record for Part I: Steroid Receptor CO-Activator 3 (SRC-3) Expression in Lung Cancer and its Role in Regulating Cancer Cell Survival and Proliferation; Part II: Development of Phosphospecific Peptoid Ligand (opens in a new tab)